ripekg:evaluation/RIPEA4A841AC6ADD4DA5B |
prov:used |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA4A841AC6ADD4DA5B |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA4A841AC6ADD4DA5B |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
ripe:concerns |
ripekg:work/10.1111%2Fpai.12978EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
ripe:recruitmentEndDate |
12-2017 |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
ripe:recruitmentEndDateExtractionRationale |
No explicit recruitment end date found. |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
ripe:recruitmentStartDate |
11-2017 |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
ripe:recruitmentStartDateExtractionRationale |
Methods: 'from November to December 2017' is used as the recruitment start date, as no specific FPI date was found. |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
ripe:studyEndDateExtractionRationale |
No explicit study end date found. |
ripekg:study-design-evidence/RIPEA4A841AC6ADD4DA5B |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA4A841AC6ADD4DA5B-inspectai-2-2 |